PMID- 31857857
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231020
IS  - 1970-5565 (Print)
IS  - 1970-5557 (Electronic)
IS  - 1970-5557 (Linking)
VI  - 13
IP  - 2
DP  - 2019 Jul 22
TI  - Efficacy and safety profiles of programmed cell death-1/programmed cell death 
      ligand-1 inhibitors in the treatment of triple-negative breast cancer: A 
      comprehensive systematic review.
PG  - 425
LID - 10.4081/oncol.2019.425 [doi]
LID - 425
AB  - Triple-negative breast cancer (TNBC) is associated with worse prognosis, with 
      limited treatment regiments available and higher mortality rate. Immune 
      checkpoint inhibitors targeting programmed cell death-1 (PD-1) or programmed cell 
      death-ligand 1 (PD-L1) showed great potentials in treating malignancies and may 
      serve as potential therapies for TNBC. This systematic review aims to evaluate 
      the efficacy and safety profiles of PD-1/PD-L1 inhibitors in the treatment of 
      TNBC. Literature search was performed via PubMed, EBSCOhost, Scopus, and CENTRAL 
      databases, selecting studies which evaluated the use of anti-PD-1/PDL1 for TNBC 
      from inception until February 2019. Risk of bias was assessed by the 
      Newcastle-Ottawa Scale (NOS). Overall, 7 studies evaluating outcomes of 1395 
      patients with TNBC were included in this systematic review. Anti-PD-1/PD-L1 
      showed significant antitumor effect, proven by their promising response 
      (objective response rate (ORR), 18.5-39.4%) and survival rates (median overall 
      survival (OS), 9.2-21.3 months). Moreover, anti- PD-1/PD-L1 yielded better 
      outcomes when given as first-line therapy, and overexpression of PD-L1 in tumors 
      showed better therapeutic effects. On the other hands, safety profiles were 
      similar across agents and generally acceptable, with grade >/=3 treatment- related 
      adverse effects (AEs) ranging from 9.5% to 15.6% and no new AEs were experienced 
      by TNBC patients. Most grade >/=3 AEs are immune-mediated, which are manifested as 
      neutropenia, fatigue, peripheral neuropathy, and anemia. PD-1/PD-L1 inhibitors 
      showed promising efficacy and tolerable AEs, and thus may benefit TNBC patients. 
      Further studies of randomized controlled trials with larger populations are 
      needed to better confirm the potential of these agents.
CI  - (c)Copyright: the Author(s), 2019.
FAU - Lazarus, Gilbert
AU  - Lazarus G
AD  - Faculty of Medicine, Universitas Indonesia, Indonesia.
FAU - Audrey, Jessica
AU  - Audrey J
AD  - Faculty of Medicine, Universitas Indonesia, Indonesia.
FAU - Iskandar, Anthony William Brian
AU  - Iskandar AWB
AD  - Faculty of Medicine, Universitas Indonesia, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20191010
PL  - Switzerland
TA  - Oncol Rev
JT  - Oncology reviews
JID - 101519906
PMC - PMC6886008
OTO - NOTNLM
OT  - Checkpoint inhibitor
OT  - programmed cell death-1
OT  - programmed cell death-ligand 1
OT  - triple-negative breast cancer
COIS- Conflicts of interest: the authors declare no conflicts of interest.
EDAT- 2019/12/21 06:00
MHDA- 2019/12/21 06:01
PMCR- 2019/10/10
CRDT- 2019/12/21 06:00
PHST- 2019/04/10 00:00 [received]
PHST- 2019/10/09 00:00 [accepted]
PHST- 2019/12/21 06:00 [entrez]
PHST- 2019/12/21 06:00 [pubmed]
PHST- 2019/12/21 06:01 [medline]
PHST- 2019/10/10 00:00 [pmc-release]
AID - 10.4081/oncol.2019.425 [doi]
PST - epublish
SO  - Oncol Rev. 2019 Oct 10;13(2):425. doi: 10.4081/oncol.2019.425. eCollection 2019 
      Jul 22.